Cimeio Therapeutics

Executive Summary

Cimeio Therapeutics is a private, Basel, Switzerland and Cambridge, MA-based biotechnology company pioneering a novel platform called Shielded-Cell & Immunotherapy Pairs (SCIP). Founded in 2021, the company aims to transform hematopoietic stem cell transplantation (HSCT) by combining gene editing with targeted immunotherapy. The SCIP platform involves engineering donor stem cells to evade immune rejection (shielded cells) while selectively depleting unshielded host cells using an immunotherapy pair. This approach could reduce the need for toxic conditioning regimens and enable safer, more effective transplants for a range of hematologic disorders. Cimeio's technology addresses key limitations of current HSCT, such as graft failure, graft-versus-host disease, and limited donor availability. The company is advancing its platform toward clinical validation, with a focus on generating preclinical proof-of-concept data and engaging with regulatory authorities. As a young company in the competitive cell and gene therapy space, Cimeio's differentiation lies in its dual shielding and depletion strategy, which offers potential advantages over existing approaches like CRISPR-based editing alone. The company's progress will hinge on demonstrating efficacy and safety in preclinical models and ultimately in human trials.

Upcoming Catalysts (preview)

• Q2 2026Preclinical Proof-of-Concept Data for Lead SCIP Candidate50% success
• Q4 2026IND Submission for First-in-Human Study40% success
• 2026Strategic Partnership or Collaboration Agreement30% success